Q3 loss narrows to $9.0M; YUPELRI sales up 9%; SVP R&D to depart Feb 2024

Theravance Biopharma, Inc.

2023-Q3 EPS reported -$0.81 revenue$39,859,000

GAAP net loss from continuing ops $9.0M vs $16.0M prior year; non-GAAP loss $0.7M (improved from $7.1M).
YUPELRI net sales $58.3M (up 9% YoY, 6% QoQ); implied 35% share $20.4M.
Richard Graham, SVP R&D, to depart Feb 29, 2024; part-time from Jan 1; Áine Miller promoted to SVP Development.
Share buybacks $30.8M in Q3; $294.6M total; $30.4M remaining; program expected to complete by year-end 2023.
PIFR-2 study enrollment complete; top-line data Jan 2024. CYPRESS last patient enrollment H2 2024.

item 2.02 item 9.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard Graham

Senior Vice President, Research & Development

TBPH · Theravance Biopharma, Inc.

Effective: 2024-02-29
Filed: November 7, 2023, 6:59 PM ET

In connection with internal changes at Theravance Biopharma, Inc., Richard Graham, Ph.D., Senior Vice President, Research & Development will be leaving the Company on or around February 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theravance Biopharma, Inc. reported the third quarter of 2023 results: revenue $15.7 million, net income $9.0 million.

Period: the third quarter of 2023
Revenue: $15.7 million
Net income: $9.0 million
Result: reported results

Exact text from the filing

Total revenue for the third quarter of 2023 was $15.7 million

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Graham departed as Senior Vice President, Research & Development at Theravance Biopharma, Inc..

Action: will be leaving
Role: Senior Vice President, Research & Development

Exact text from the filing

In connection with internal changes at Theravance Biopharma, Inc., Richard Graham, Ph.D., Senior Vice President, Research & Development will be leaving the Company on or around February 29, 2024.

View on SEC.gov

Browse all earnings releases →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-115296

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.